Alder BioPharmaceuticals (ALDR) Tops Q4 EPS by 1c
Get Alerts ALDR Hot Sheet
Join SI Premium – FREE
Alder BioPharmaceuticals (NASDAQ: ALDR) reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $5.7 million.
For earnings history and earnings-related data on Alder BioPharmaceuticals (ALDR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
- Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!